Amenez votre candidat médicament au sommet! • PhinC Development

John DiBella

President, Lancaster Division - Simulations Plus, Inc. (NASDAQ: SLP)

Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity.

Olivier Lacombe

Head of Pharmacokinetics - Inventiva

Inventiva and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs.

Antoine Tarral

Head of HAT Clinical Programme - DNDi

The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program.

Pascal Benderitter

Senior Program Director NCX - Oncodesign Precision Medicine

In the frame of the preclinical development of our main asset, we have been looking after experts in the modeling of pharmacokinetics. Working with PhinC, a member of the AFFSSI, has only seemed natural in regards with their recognized expertise and by a common vision of long-term collaboration. Their work on a PBPK model was a clear added value in the regulatory filing and contributed to the approval of the clinical trial application early 2023. We are happy to count them among the key players in the ongoing clinical study on ODS-101.

Sakina Sayah-Jeanne

Senior Director, Translational R&D - Da Volterra

PhinC has been accompanying Da Volterra for several years on PBPK Modelling activities. Our collaboration, based on mutual trust, has already been very fruitful and has allowed Da Volterra to gain precious knowledge on its product under development. Da Volterra enjoys working with PhinC and will continue to do so in the years to come, leaning from its expertise.

Agnes Hemon

Preclinical and PK Clinical Officer - HRA Pharma

PhinC is one of HRA Pharma’s valuable partners for pharmacokinetic studies. From just advice to modeling, we know we can trust them to efficiently support and carry out our projects.

Votre Partenaire en Modélisation & Simulation Pharmacocinétique !

Actualités

10 bonnes raisons d'utiliser la modélisation et la simulation

Actualités

PhinC fête ses 15 ans !

Actualités

Nouvel article : Unlocking the power of PBPK prediction

Ils nous font confiance